Denosumab(Others Approved) 60 mg, 120 mg Suppliers & Bulk Manufacturers
Available Forms: Subcutaneous injection
Available Strengths: 60 mg, 120 mg
Reference Brands: Xgeva(US & EU) Ospomyv, Xbryk, Merilog, Stoboclo, Zadenvi, Enwylma, Denbrayce, Izamby - biosimilar to Xgeva
Category: Biosimilars
Biosimilars of Xgeva (denosumab) inhibit RANKL, preventing osteoclast formation and activity. They reduce bone destruction, fractures, and skeletal-related events in cancer and osteoporosis patients. Benefits include similar efficacy, lower costs, increased treatment access, and support for patient bone health when used under medical supervision.
Product Description:
Biosimilars of Xgeva (denosumab) are regulated in the EU and US, supported by dossiers demonstrating biosimilarity, safety, efficacy, and manufacturing quality in compliance with GMP standards. In the US, FDA approval involves extensive comparison, clinical validation, and safety data. In the EU, CE marking certifies conformity under the MDR. These biosimilars undergo validation, stability testing, and audits, supported by comprehensive documentation including biosimilarity, clinical trial data, safety profiles, and manufacturing practices. For licensing procedures, approved dossiers, and the latest regulatory updates, visit Pharmatradz. Ensuring compliance guarantees access to affordable, high-quality denosumab biosimilars, supporting osteoporosis and bone metastasis treatment worldwide.
Denosumab(Others Approved) — third party manufacturing & bulk supply
Denosumab(Others Approved) 60 mg, 120 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Indicative minimum order quantity
Denosumab(Others Approved) is supplied as Subcutaneous injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.
Manufacturers of Denosumab(Others Approved) listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Denosumab(Others Approved) →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Related Products
Insulin‑Aspart‑Szjj
Strength:
100 units/mL
Form: SQ Injection
Reference Brands: NovoLog; Merilog is biosimilar to NovoLog.
View Details
Eculizumab‑Aeeb
Strength:
300 mg/20 mL (IV infusion),
Form: Injection for intravenous infusion
Reference Brands: Soliris, Bkemv- Biosimilar of Soliris, Epysqli- Biosimilar of Soliris
View Details
Omalizumab‑Igec
Strength:
75 mg/0.5 mL and 150 mg/mL
Form: Pre filled syringe
Reference Brands: Xolair, Omlyclo - a Biosimilar to Xolair
View Details
Tocilizumab-Bavi
Strength:
80 mg/4ml
Form: Intravenous infusion
Reference Brands: Actemra; Tofidence - biosimilar to Actemra (tocilizumab).
View DetailsQuick Response Guaranteed | Verified Suppliers
